Surgical Resection for Pulmonary Carcinoid: Long-Term Results of Multicentric Study-The Importance of Pathological N Status, More Than We Thought

Overview

Journal Lung

Specialty Pulmonary Medicine

Date 2017 Oct 13

PMID 29022070

Citations 17

Authors

Giacomo Cusumano

Ludovic Fournel

Salvatore Strano

Diane Damotte

Marie Christine Charpentier

Antonio Galia

Alberto Terminella

Maurizio Nicolosi

Jean Francois Regnard

Marco Alifano

Affiliations

Soon will be listed here.

Abstract

Background: Histological subdivision into typical (TC) and atypical (AC) is crucial for treatment and prognosis of lung carcinoids but can be also very challenging, even for experts. In this study, we aimed to strengthen or reduce the prognostic value of several pathological, clinical, or per-operative factors some of which are still controversial.

Methods: We retrospectively reviewed clinical records related to 195 patients affected by TC (159) or AC (36) surgically treated between 2000 and 2014, in three different centers. Survival and subtypes comparison analyses were performed to identify potential prognostic factors.

Results: TCs showed a lower rate of nodal involvement than ACs (N0 = 94.9%; N1 = 1.9%; N2 = 3.2% in typical and N0 = 63.8%; N1 = 16.6%; N2 = 19.4% in atypical carcinoids, respectively, p < 0.0001). Long-term oncological results of resected carcinoids were significantly better in TCs than ACs with higher 5- and 10-year overall survival rates (97.2 and 88.2% vs. 77.9 and 68.2%, respectively; p = 0.001) and disease-free survival rates (98.2 and 90.3% in typical and 80.8 and 70.7% atypical carcinoids, respectively; p = 0.001). Risk factors analysis revealed that AC subtype [HR 4.33 (95% CI 1.72-8.03), p = 0.002], pathological nodal involvement [HR 3.05 (95% CI 1.77-5.26), p < 0.0001], and higher SUV [HR 4.33 (95% CI 1.03-7.18), p = 0.002] were independently and pejoratively associated with overall survival. Factors associated with a higher risk of recurrence were AC subtype [HR 6.13 (95% CI 1.13-18.86), p = 0.002]; nodal involvement [HR 5.48 (95% CI 2.85-10.51), p < 0.0001]; higher Ki67 expression level [HR 1.09 (95% CI 1.01-1.20), p = 0.047]; and SUV [HR 1.83 (95% CI 1.04-3.23), p = 0.035].

Conclusion: Surgery for lung carcinoids allows satisfactory oncological results which mainly depend on carcinoid subtype dichotomy, pathological nodal status, and SUV.

Citing Articles

The presentation pattern and surgical strategies in bronchopulmonary carcinoid tumors: a multicenter experience in a low-income country.

Deme W, Merine S, Wadaja D, Gemeda A, Demissie M, Bahta M Front Surg. 2024; 11:1399999.

PMID: 39239472 PMC: 11374608. DOI: 10.3389/fsurg.2024.1399999.

Prognostic factors of recurrence and disease-free survival in radically resected pulmonary carcinoids: a real-world analysis.

Spils M, Klikovits T, Krenbek D, Hochmair M, Jankovic I, Schulte L J Thorac Dis. 2024; 16(3):1911-1922.

PMID: 38617753 PMC: 11009585. DOI: 10.21037/jtd-23-1681.

HSP90 expression is associated with outcome in pulmonary carcinoid tumor patients.

Niinimaki J, Sihto H, Arola J, Vesterinen T Transl Lung Cancer Res. 2023; 12(9):1876-1886.

PMID: 37854156 PMC: 10579826. DOI: 10.21037/tlcr-23-304.

A Competing Risk Model Nomogram to Predict the Long-Term Prognosis of Lung Carcinoid.

Wang T, Zhou J, Zheng Q, Wu D, Lu T, Lin M Ann Surg Oncol. 2023; 30(9):5830-5839.

PMID: 36917336 DOI: 10.1245/s10434-023-13333-6.

A Multimodal Biomarker Predicts Dissemination of Bronchial Carcinoid.

Reuling E, Naves D, Kortman P, Broeckaert M, Plaisier P, Dickhoff C Cancers (Basel). 2022; 14(13).

PMID: 35805004 PMC: 9265109. DOI: 10.3390/cancers14133234.

References

Hassan M, Phan A, Li D, Dagohoy C, Leary C, Yao J . Risk factors associated with neuroendocrine tumors: A U.S.-based case-control study. Int J Cancer. 2008; 123(4):867-73. DOI: 10.1002/ijc.23529. View

Modlin I, Sandor A . An analysis of 8305 cases of carcinoid tumors. Cancer. 1997; 79(4):813-29. DOI: 10.1002/(sici)1097-0142(19970215)79:4<813::aid-cncr19>3.0.co;2-2. View

Cafarotti S, Cesario A, Margaritora S, Granone P . Typical bronchial carcinoid tumors: focus on surgical management. Ann Thorac Surg. 2013; 95(1):385. DOI: 10.1016/j.athoracsur.2012.05.119. View

Yao J, Hassan M, Phan A, Dagohoy C, Leary C, Mares J . One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008; 26(18):3063-72. DOI: 10.1200/JCO.2007.15.4377. View

Tastepe A, Kurul I, Demircan S, Liman S, Kaya S, Cetin G . Long-term survival following bronchotomy for polypoid bronchial carcinoid tumours. Eur J Cardiothorac Surg. 1999; 14(6):575-7. DOI: 10.1016/s1010-7940(98)00239-5. View

Yendamuri S, Gold D, Jayaprakash V, Dexter E, Nwogu C, Demmy T . Is sublobar resection sufficient for carcinoid tumors?. Ann Thorac Surg. 2011; 92(5):1774-8. DOI: 10.1016/j.athoracsur.2010.08.080. View

Raz D, Nelson R, Grannis F, Kim J . Natural history of typical pulmonary carcinoid tumors: a comparison of nonsurgical and surgical treatment. Chest. 2014; 147(4):1111-1117. PMC: 4388119. DOI: 10.1378/chest.14-1960. View

Cardillo G, Sera F, Di Martino M, Graziano P, Giunti R, Carbone L . Bronchial carcinoid tumors: nodal status and long-term survival after resection. Ann Thorac Surg. 2004; 77(5):1781-5. DOI: 10.1016/j.athoracsur.2003.10.089. View

Wartski M, Alberini J, Leroy-Ladurie F, de Montpreville V, Nguyen C, Corone C . Typical and atypical bronchopulmonary carcinoid tumors on FDG PET/CT imaging. Clin Nucl Med. 2004; 29(11):752-3. DOI: 10.1097/00003072-200411000-00026. View

10.

Filosso P, Rena O, Donati G, Casadio C, Ruffini E, Papalia E . Bronchial carcinoid tumors: surgical management and long-term outcome. J Thorac Cardiovasc Surg. 2002; 123(2):303-9. DOI: 10.1067/mtc.2002.119886. View

11.

Jindal T, Kumar A, Venkitaraman B, Meena M, Kumar R, Malhotra A . Evaluation of the role of [18F]FDG-PET/CT and [68Ga]DOTATOC-PET/CT in differentiating typical and atypical pulmonary carcinoids. Cancer Imaging. 2011; 11:70-5. PMC: 3205752. DOI: 10.1102/1470-7330.2011.0010. View

12.

Mineo T, Guggino G, Mineo D, Vanni G, Ambrogi V . Relevance of lymph node micrometastases in radically resected endobronchial carcinoid tumors. Ann Thorac Surg. 2005; 80(2):428-32. DOI: 10.1016/j.athoracsur.2005.02.083. View

13.

Travis W, Brambilla E, Nicholson A, Yatabe Y, Austin J, Beasley M . The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification. J Thorac Oncol. 2015; 10(9):1243-1260. DOI: 10.1097/JTO.0000000000000630. View

14.

Canizares M, Matilla J, Cueto A, Algar J, Muguruza I, Moreno-Mata N . Atypical carcinoid tumours of the lung: prognostic factors and patterns of recurrence. Thorax. 2014; 69(7):648-53. DOI: 10.1136/thoraxjnl-2013-204102. View

15.

Fox M, van Berkel V, Bousamra 2nd M, Sloan S, Martin 2nd R . Surgical management of pulmonary carcinoid tumors: sublobar resection versus lobectomy. Am J Surg. 2012; 205(2):200-8. DOI: 10.1016/j.amjsurg.2012.05.008. View

16.

Thomas Jr C, Tazelaar H, Jett J . Typical and atypical pulmonary carcinoids : outcome in patients presenting with regional lymph node involvement. Chest. 2001; 119(4):1143-50. DOI: 10.1378/chest.119.4.1143. View

17.

Caplin M, Baudin E, Ferolla P, Filosso P, Garcia-Yuste M, Lim E . Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids. Ann Oncol. 2015; 26(8):1604-20. DOI: 10.1093/annonc/mdv041. View

18.

Brokx H, Paul M, Postmus P, Sutedja T . Long-term follow-up after first-line bronchoscopic therapy in patients with bronchial carcinoids. Thorax. 2015; 70(5):468-72. DOI: 10.1136/thoraxjnl-2014-206753. View

19.

Lococo F, Treglia G, Cesario A, Paci M, Filice A, Versari A . Functional imaging evaluation in the detection, diagnosis, and histologic differentiation of pulmonary neuroendocrine tumors. Thorac Surg Clin. 2014; 24(3):285-92. DOI: 10.1016/j.thorsurg.2014.04.004. View

20.

Ambrosini V, Nanni C, Zompatori M, Campana D, Tomassetti P, Castellucci P . (68)Ga-DOTA-NOC PET/CT in comparison with CT for the detection of bone metastasis in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2010; 37(4):722-7. DOI: 10.1007/s00259-009-1349-9. View